2025-06-12
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
2025-06-12 • David Stahl, Philipp Gödel, Hyatt Balke‐Want, Rahil Gholamipoorfard, Paul Segbers, Luis Tetenborg, Mirjam Koker, Janina Dörr, Lisa Gregor, Daniel B...
Despite the improvement, approximately 60% of patients with relapsed or refractory (r/r) aggressive B cell lymphoma (B-NHL) do not achieve durable benefit from CAR-T cell therapy. To elucidate factors associated with CAR-T therapy resistance, we conducted high-dimensional analyses of pre- and post-CAR-T cell specimens. In patients with non-durable response, we identified a prognostically relevant lymphoma-associated myeloid-monocytic (LAMM) gene signature. In-depth profiling revealed a distinct CSF1R<sup>+</sup>CD…